Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
INNOVATION THAT MATTERS By Rich Soll, Senior Advisor, Strategic Initiatives at WuXi AppTec (@richsollwx) As a self-proclaimed drug hunter, Phil Jones is...
Continue ReadingKnowledge Library
Faster with high-speed fragment screening — Accelerate your drug discovery campaign
In the past, thousands of proteins were considered undruggable. The restricted number of chemical entities available and classical methods limited...
Continue Reading
Enabling Technology for Targeted Protein Degradation
Summary Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of...
Continue Reading
Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C...
Activating KRAS mutations, including G12C and G12D, are detected in approximately 25% of human cancers. The most common KRAS mutation...
Continue Reading
Targeted Protein Degradation Platform
Integrated Services BIOLOGY & PHARMACOLOGY BINARY/TERNARY COMPLEX FORMATION Biochemical & Biophysical Assays Biochemical binding assay Cellular Assays TARGET UBIQUITINATION &...
Continue Reading Translational Oncology
Biomarker discovery Mouse clinical trial 61 PDX-derived primary cancer cell lines Drug-resistant xenograft models Combination therapy platform including radiation World...
Continue Reading Immuno-Oncology Services
Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry,...
Continue Reading Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy...
Continue Reading